Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Fanconi syndrome

Renal · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

Severe hypophosphataemia can cause respiratory weakness, encephalopathy, haemolysis or rhabdomyolysis; severe hypokalaemia can cause paralysis or arrhythmia. Dehydration, acute kidney injury, fracture, sepsis or rapidly progressive weakness also needs urgent assessment. Do not stop antiviral, chemotherapy or other essential treatment without the responsible specialty, but suspected drug-induced proximal tubulopathy requires prompt same-day coordination and biochemical review.

Synopsis

Recognise generalised proximal tubular solute wasting, identify acquired and inherited causes, and replace phosphate, alkali and potassium through safe specialist monitoring.

  • Fanconi syndrome is a generalised proximal-tubule reabsorptive defect, not Fanconi anaemia, and produces urinary loss of several filtered solutes rather than one isolated abnormality.
  • Core clues include phosphate wasting, normoglycaemic glycosuria, aminoaciduria, bicarbonate loss causing proximal RTA, urate loss, potassium loss and low-molecular-weight proteinuria.
  • A normal creatinine does not exclude substantial proximal dysfunction because tubular transport can fail before glomerular filtration falls.
  • Acquired causes include monoclonal light-chain proximal tubulopathy, tenofovir disoproxil, ifosfamide, cisplatin, outdated tetracycline exposure and heavy metals; the precise medicine and host risk matter.
  • Inherited causes present more often in childhood but can reach adult services; cystinosis, Dent and Lowe syndromes, hereditary fructose intolerance, tyrosinaemia and mitochondrial disorders have distinctive extrarenal features.
  • Renal phosphate wasting causes defective mineralisation, bone pain, proximal weakness, insufficiency fractures or rickets, sometimes before the kidney diagnosis is recognised.
  • Pair serum and urine samples to establish inappropriate urinary loss; urine glucose in the presence of normal blood glucose is a particularly useful bedside clue.
  • Management requires removal or treatment of the cause plus individual replacement of water, bicarbonate, potassium and phosphate; oversupplementation can cause diarrhoea, hyperkalaemia or nephrocalcinosis.

Key red flags

Phosphate depletion

Bone pain, waddling gait, proximal weakness and insufficiency fractures with low phosphate may represent renal-wasting osteomalacia rather than osteoporosis alone.

Drug-associated syndrome

Rising creatinine, hypophosphataemia and glycosuria during tenofovir disoproxil or ifosfamide exposure should trigger targeted renal safety review.

Investigation priorities

01
Paired serum and urine chemistryFirst step

Demonstrate inappropriate renal loss of phosphate, glucose, urate, bicarbonate and potassium.

Management branches

DetectConfirm multi-solute wasting

Hypophosphataemia, glycosuria or tubular proteinuria suggests proximal dysfunction.

  1. Repeat serum phosphate, bicarbonate, potassium, glucose, urate, magnesium and creatinine while collecting appropriately timed urine chemistry.
  2. Demonstrate at least a coherent pattern of inappropriate urinary losses rather than diagnosing Fanconi syndrome from isolated glycosuria.
  3. Assess symptoms and ECG where needed, admitting for severe phosphate or potassium depletion, dehydration, rhabdomyolysis or neurological compromise.

Key medicines

Oral phosphate saltsStart only with renal or metabolic specialist advice, using divided local-formulary doses titrated to symptoms, serum phosphate and urinary calcium rather than normalising one result rapidly.Can cause diarrhoea, secondary hyperparathyroidism, hyperphosphataemia and nephrocalcinosis. Dose requirements change as tubular function and GFR change.
Alfacalcidol or calcitriolUse only for a defined specialist indication with an agreed low starting dose and frequent calcium, phosphate and urine-calcium surveillance.Hypercalcaemia, hypercalciuria, stones and nephrocalcinosis can result; native vitamin-D deficiency should be assessed separately and pregnancy requires specialist review.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NHS Greater Glasgow renal tubular disease guidelinePrimary NHS description of proximal solute losses; paediatric replacement doses are not general adult regimens.
  • UK Kidney Association tubulopathy groupUK rare-disease framework covering inherited, drug-induced and heavy-metal Fanconi syndromes.
  • Tenofovir disoproxil UK SmPCCurrent proximal-tubulopathy warnings, renal thresholds and monitoring requirements.
  • UK Kidney Association cystinosis informationUK explanation of inherited proximal tubular wasting in cystinosis.
  • NICE chronic kidney disease recommendationsGeneral kidney-function assessment and referral safeguards.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom